Risk factors for humoral myocardial rejection during the first year after heart transplantation

Read full text Summarise with VIRAT
Authors: Yu. V. Sazonova, П. А. Федотов, M A Bortzova, Maria Simonenko, L. O. Korneva, Daria Kilina, А. С. Головкин, O. V. Kalinina, M. Yu. Sitnikova, G. V. Nikolaev, М. А. Карпенко
Cited by: 0
References: 15

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Objective: to identify risk factors for antibody-mediated myocardial rejection (AMR) during the first year following heart transplantation (HT). Materials and methods. This retrospective study included 162 patients who underwent HT at Almazov National Medical Research Centre between 2010 and 2024. Clinical, laboratory, immunological, and morphological data were analyzed. Sensitization was assessed using Luminex multiplex assays and solid-phase ELISA. AMR was diagnosed based on endomyocardial biopsy with morphological and immunohistochemical evaluation in accordance with the 2013 ISHLT classification. Hemodynamically significant rejection was defined as AMR II–III in combination with graft dysfunction and/or the presence of donorspecific antibodies (DSA). Patients were stratified into three groups: (1) no sign of AMR (control); (2) isolated morphological signs of AMR (AMR II); and (3) hemodynamically significant AMR (AMR III, or AMR II with DSA and/or echocardiographic evidence of graft dysfunction). Discriminant analysis was used to evaluate the factors associated with the development of AMR. Results. Morphological signs of AMR were identified in 36.2% of patients, including 9.9% with hemodynamically significant rejection requiring specific therapy. Patients with AMR before HT showed significantly higher sensitization to HLA class I and II antigens (MFI >5000; p < 0.05), and following HT, a statistically significant excess of de novo antibodies persisted for 6–12 months compared with the control group (p < 0.05). In addition, AMR was associated with lower tacrolimus levels during the first two weeks after HT (p = 0.002) and reduced antimetabolite doses in the first month post-transplant (p < 0.001). Discriminant analysis of 15 variables yielded a model incorporating 9 significant predictors, enabling statistically reliable differentiation of patients with hemodynamically significant rejection from other groups (F(18,222) = 12.463; p < 0.00001). Conclusion. High levels of HLA sensitization before transplantation, suboptimal immunosuppression in the early postoperative period, and predictors identified in the discriminant analysis model are associated with an increased risk of developing hemodynamically significant AMR. The proposed model may be used for risk stratification and to individualize post-transplant follow-up.

Fields of Study & Subjects

Transplantation: Methods and Outcomes Renal Transplantation Outcomes and Treatments Organ and Tissue Transplantation Research

Publication details

Journal / source
Russian Journal of Transplantology and Artificial Organs
Volume
28
Issue
1
Pages
128–137
Publication date
31 March 2026
Language
EN